APYX: Apyx Medical Corporation Stock

by  •  • Comments Off on APYX: Apyx Medical Corporation Stock

SIC 3841 – Surgical and Medical Instruments and Apparatus

Valuation
Market Cap ($M) 49.19
Enterprise Value ($M) 38.95
Book Value ($M) 26.92
Book Value / Share 0.78
Price / Book 1.83
NCAV ($M) 18.04
NCAV / Share 0.52
Price / NCAV 2.73

Profitability (mra)
Return on Invested Capital (ROIC) -0.29
Return on Assets (ROA) -0.33
Return on Equity (ROE) -0.52

Liquidity (mrq)
Quick Ratio 4.74
Current Ratio 5.52

Balance Sheet (mrq) ($M)
Current Assets 70.36
Assets 79.24
Liabilities 52.32
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 52.35
Operating Income -19.95
Net Income -18.71
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -5.25
Cash from Investing 6.73
Cash from Financing 32.17

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-05 13D Archon Capital Management LLC 9.96 0.00
04-01 13D Vizirgianakis Stavros G. 5.04
03-25 13G/A Hirschman Orin 0.00 -100.00
02-14 13G/A Rtw Investments, Lp 3.00 -69.81
02-14 13G/A Divisadero Street Capital Management, LP 0.00 -100.00
02-14 13G/A Pura Vida Investments, Llc 0.23 -96.50
02-02 13G/A Cowen Financial Products LLC 0.00 -100.00
01-23 13G Royce & Associates Lp 6.23

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SE
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSU
2023-08-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT T
2023-05-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-03 2,001 13,325 15.02
2024-05-02 1,444 2,760 52.32
2024-05-01 1,661 3,145 52.81
2024-04-30 43,540 10,502 414.59

(click for more detail)

Similar Companies
ALGN – Align Technology, Inc. ANGO – AngioDynamics, Inc.
ANIK – Anika Therapeutics, Inc. ARAY – Accuray Incorporated
ATEC – Alphatec Holdings, Inc.


Financial data and stock pages provided by
Fintel.io